ALNY Alnylam Pharmaceuticals

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Alnylam Pharmaceuticals (ALNY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No quarterly revenue or YoY figures disclosed in this MD&A excerpt
• No profitability or margin data provided for current quarter or YoY comparison

+3 more insights

Risk Factors

• New risk: AMVUTTRA U.S. launch March 2025 for ATTR amyloidosis with cardiomyopathy increases commercialization risk
• Updated financial risk: Accumulated deficit $7.16B as of Sept 30, 2025; product revenues $851.1M Q3, $1.99B YTD with ongoing operating losses

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.2B

▲ +149.3% YoY▲ +61.4% QoQ

Net Income

$251M

▲ +325.0% YoY▲ +478.8% QoQ

Net Margin

20.1%

▲ +4238bp YoY▲ +2867bp QoQ

Source: XBRL data from Alnylam Pharmaceuticals Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Alnylam Pharmaceuticals Quarterly Reports

Q2 2025 10-Q

Get deeper insights on Alnylam Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.